These results are considered as definitive evidences that WL has affirmative AMPK up-regulation mediated suppressing lipogenesis and promoting fatty acid oxidation related lipid metabolism improvement activities in HFD supplied mice, dose-dependently, and as similar to metformin 250 mg/kg at oral dose of 50 mg/kg, enough to be developed as an ingredient of medicinal food and natural drugs for obese type II diabetes through AMPK and lipid metabolism related gene mRNA expression modulations, at least in a condition of the present analysis (Table 16). This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.